About four years after launch, Orna Therapeutics Inc. signed its second major deal, this time validating the lipid nanoparticle delivery technology it acquired through its Renagade Therapeutics Inc.

Vertex Pharmaceuticals Inc. closed $111.56 below its 52-week high ($519.88), which the company achieved on November 8th.

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell ...

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and ...

Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.

Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

Orna Therapeutics, through its wholly owned subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with ...

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

Klick Health is taking a fellow life-sci-centric agency under its wing. | Klick Health is taking a fellow life-sci-centric ...